Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.tips.2020.11.014
Title: Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age
Authors: Thng, Dexter Kai Hao
Toh, Tan Boon 
Chow, Edward Kai-Hua 
Keywords: cancer
computational
drug targets
MYC
synthetic lethality
Issue Date: 1-Mar-2021
Publisher: Elsevier Ltd
Citation: Thng, Dexter Kai Hao, Toh, Tan Boon, Chow, Edward Kai-Hua (2021-03-01). Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age. Trends in Pharmacological Sciences 42 (3) : 166-182. ScholarBank@NUS Repository. https://doi.org/10.1016/j.tips.2020.11.014
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Abstract: Deregulation of MYC is among the most frequent oncogenic drivers of cancer. Developing targeted therapies against MYC is, therefore, one of the most critical unmet needs of cancer therapy. Unfortunately, MYC has been labelled as undruggable due to the lack of success in developing clinically relevant MYC-targeted therapies. Synthetic lethality is a promising approach that targets MYC-dependent vulnerabilities in cancer. However, translating the synthetic lethality targets to the clinics is still challenging due to the complex nature of cancers. This review highlights the most promising mechanisms of MYC synthetic lethality and how these discoveries are currently translated into the clinic. Finally, we discuss how in silico computational platforms can improve clinical success of synthetic lethality-based therapy. © 2020 The Author(s)
Source Title: Trends in Pharmacological Sciences
URI: https://scholarbank.nus.edu.sg/handle/10635/232943
ISSN: 0165-6147
DOI: 10.1016/j.tips.2020.11.014
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1016_j_tips_2020_11_014.pdf2.37 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons